Based on a long view of profit potential, a number of drug stocks trade at lower valuations than...

|By:, SA News Editor

Based on a long view of profit potential, a number of drug stocks trade at lower valuations than peers, SmartMoney says. After weeding out firms facing major patent issues in coming years, six winners should emerge: Glaxo (GSK +0.4%), Roche (RHHBY.PK -0.9%), Pfizer (PFE -1.9%), Sanofi (SNY -0.7%), Merck (MRK +0.8%), Novartis (NVS +0.3%).